Capital Spending Guidance for 2025: $800 million to $850 million. Stryker Corp (NYSE:SYK) reported impressive organic sales growth exceeding 10% for both Q4 and the full year 2024. The company ...

Learn more about whether Edwards Lifesciences Corporation or Stryker Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stryker Corp (SYK) reports over 10% organic sales growth and outlines strategic acquisitions amidst challenges in its Q4 2024 earnings call. Stryker ( NYSE:SYK ) Full Year 2024 Results Key ...

Q4 2024 Earnings Call Transcript January 28, 2025 Stryker Corporation beats earnings expectations. Reported EPS is $4.01, ...

(d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and ...

Medical technology company Stryker (NYSE:SYK) reported in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its ...

2025 Guidance for Organic Sales Growth: 8% to 9%. 2025 Adjusted EPS Guidance: $13.45 to $13.70 per share. Cash and Marketable Securities: $4.5 billion at year-end. Total Debt: Approximately $13.6 ...

28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Reported net sales increased 10.7% to $6.4 billion ...

Stryker Corporation (NYSE:SYK), a prominent player in the medical technology sector ... ratio of 50.09. The company’s price-to-sales ratio of 6.63 indicates investor confidence in its ...

Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.

Welcome to the fourth quarter 2024 Stryker earnings call. My name is Luke ... Against double-digit comparatives from a year ago, organic sales growth exceeded 10% for both Q4 and the full year.